J Prev Alz Dis 2022; Original Research Published online March 18, 2022, http://dx.doi.org/10.14283/jpad.2022.30 © The Author(s) 2022 Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease S. Budd Haeberlein1, P.S. Aisen2, F. Barkhof3,4,...
More
J Prev Alz Dis 2022; Original Research Published online March 18, 2022, http://dx.doi.org/10.14283/jpad.2022.30 © The Author(s) 2022 Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease S. Budd Haeberlein1, P.S. Aisen2, F. Barkhof3,4, S. Chalkias1,*, T. Chen1, S. Cohen5, G. Dent1, O. Hansson6,7, K. Harrison1, C. von Hehn1,*, T. Iwatsubo8, C. Mallinckrodt1,*, C.J. Mummery9, K.K. Muralidharan1, I. Nestorov1, L. Nisenbaum1,*, R. Rajagovindan1,*, L. Skordos1,*, Y. Tian1, C.H. van Dyck10, B. Vellas11, S. Wu1, Y. Zhu1, A. Sandrock1,* 1. Biogen, Cambridge, MA, USA; 2. Alzheimer’s Therapeutic Research Institute, University of Southern California, San Diego, CA, USA; 3. Department of Radiology and Nuclear Medicine, Amsterdam UMC, Amsterdam, the Netherlands; 4. UCL Queen Square Institute of Neurology & Centre for Medical Image Computing, London, UK; 5. Toronto Memory Program, Toronto, ON, Canada; 6. Clinical Memory Research Unit, Department of Clinical Sciences, Lund Univers
Less
